← Who reports today · Health Care
SOLV · Q2 2026
Archived report (Q2 2026). Latest deep dive →
Net income
$92M
up 2.2% y/y
Total net sales
$2,209M
up 2.2% y/y
Operating income
$181M
down 15.4% y/y
Gross profit
$1,286M
up 9.4% y/y
The quarter in brief
Revenue grew 2.2% y/y to $2.21B, operating margin 8.2% vs 9.9%, net income $92M (+2.2% y/y).
All figures in $M.
| Line item | Amount and change |
|---|---|
| Net sales of product | $1,698 · +1.8% |
| Net sales of software and rentals | $511 · +3.7% |
| Total net sales | $2,209 · +2.2% |
| Cost of product | $807 · −6.7% |
| Cost of software and rentals | $116 · −4.1% |
| Gross profit | $1,286 · +9.4% · 58.2% margin |
| Selling, general and administrative expenses | $927 · +20.1% |
| Research and development expenses | $178 · −5.8% |
| Operating income | $181 · −15.4% · 8.2% margin |
| Interest expense, net | $64 · −37.9% |
| Other expense (income), net | $9 · +12.5% |
| Income before income taxes | $108 · +4.9% |
| Provision for (benefit from) income taxes | $15 · +15.4% · 13.9% effective rate |
| Net income | $92 · +2.2% · $0.53/sh · 4.2% margin |
Verdict: revenue grew 2.2% y/y to $2.21B, operating margin 8.2% vs 9.9%, net income $92M (+2.2% y/y).
Operating cash flow was $227 million and free cash flow was $144 million.
Source and notation
Source: Solventum press release, 8-K EX-99.1 of 08/05/2026 (SEC EDGAR). Every figure was matched against the income statement in the release and checked against SEC XBRL.
Open as an image: SOLV, Q2 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0
Cite / embed this chart
Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).
Chart: “SOLV Q2 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/solv/q2-2026. Licensed under CC BY 4.0.
<figure> <a href="https://whoreportstoday.com/t/solv/q2-2026"><img src="https://whoreportstoday.com/t/solv/q2-2026/sankey.png" alt="SOLV Q2 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a> <figcaption>Source: <a href="https://whoreportstoday.com/t/solv/q2-2026">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption> </figure>
https://whoreportstoday.com/t/solv/q2-2026/sankey.png
<a href="https://whoreportstoday.com/t/solv/q2-2026">SOLV Q2 2026 earnings chart (Who Reports Today)</a>
This is an archived report: the image at this link won’t change. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.
- Organic sales rose 9.5%, while reported sales rose 2.2%.
- Gross margin was 58.2% vs 54.4% a year earlier.
- Operating income was $181M, a 8.2% margin vs 9.9% a year earlier.
- The effective tax rate was 13.9% vs 12.6% a year earlier.
- Diluted EPS was $0.53 vs $0.51 a year earlier.
What distorts the picture in this report and what to watch beyond the headlines.
SOLV — a healthcare company spun off from 3M that makes wound care, surgical, sterilization and infection-prevention products, dental and orthodontic products, and clinical documentation and coding software for hospitals, clinics and dental practices.
After selling its Purification & Filtration business to Thermo Fisher, it earns money in three segments: MedSurg (57.9% of 2025 sales), Dental Solutions and Health Information Systems. · Source: annual report (Form 10-K, SEC)
More reports: STE · Q2 FY2027 · SYK · Q3 2026 · TECH · Q1 FY2027 · TMO · Q3 2026 · UHS · Q3 2026 · UNH · Q3 2026 · VEEV · Q2 FY2027 · VRTX · Q3 2026 · VTRS · Q3 2026 · WAT · Q3 2026 · all reports